IRD

#3253
Opus Genetics, Inc. - Common Stock
3.8 3 USD
+0.06%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
3.83
3.83
Intervallo Annuale
2.82
5.81
Variazione giornaliera
+5.80%
Variazione Mensile
+2.96%
Variazione di 6 mesi
-9.24%
Variazione Annuale
+2.96%
Chiusura Precedente
3.6 2
Open
3.8 3
Minimo
3.8 3
Massimo
3.8 3
Volume
73
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Opus Genetics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Opus Genetics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Opus Genetics, Inc. quarterly report, Q1 FY2026
10-Q

Opus Genetics, Inc. current report, 12 February 2024

Full document

Business Context and Reporting Period

This Form 8-K filing by Ocuphire Pharma, Inc. (OCUP) reports a corporate governance event dated February 12, 2024. The filing announces the appointment of a new Chief Financial Officer (CFO) and details the associated employment agreement.

Key Financial Metrics

The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and appointment details.

Material Changes

The primary material change is the appointment of Nirav Jhaveri as Chief Financial Officer, effective February 12, 2024. He replaces Amy Rabourn, who served as Senior Vice President of Finance on an interim basis.

Management Commentary and Compensation Details

Mr. Jhaveri brings prior experience as CFO of Insilico Medicine (2021-2023) and Journey Medical Corporation (2020-2021). His employment agreement includes the following compensation terms:

  • Base Salary: $410,000 annualized.
  • Stock Option Award: 210,000 shares under the 2021 Inducement Plan. Vesting: 25% on the first anniversary, with the balance vesting quarterly over the next three years.
  • Restricted Stock Award (RSU): 140,000 shares. Vesting: 4 equal annual installments over four years.
  • Annual Bonus: Discretionary cash bonus up to 45% of base salary based on performance goals.
  • Severance: 0.75x sum of annual base salary and prorated target bonus if terminated without cause or for Good Reason. Payments made in nine equal installments.
  • Change of Control: Lump sum payment of 0.75x sum of annual base salary and target bonus, plus full acceleration of remaining equity awards if terminated within 12 months of a Change of Control.

Investor Verification Checklist

  • Verify the full text of the Employment Agreement (Exhibit 10.1) and First Amendment (Exhibit 10.2) for specific definitions of "Good Reason" and "Change of Control."
  • Confirm the impact of the new equity awards on total share count and potential dilution.
  • Review the company's cash position to assess the ability to fund the new executive's base salary and potential severance obligations.
  • Check for any subsequent filings regarding the departure of the interim CFO, Amy Rabourn.